NCT07081022 JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
| NCT ID | NCT07081022 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Condition | B-cell Non-Hodgkin's Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-08-17 |
| Primary Completion | 2027-04-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 180 participants in total. It began in 2025-08-17 with a primary completion date of 2027-04-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Eligibility Criteria
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be enrolled： * Age range: 18 to 80 years old (inclusive), both male and female are acceptable； * ECOG: 0-2； * B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed； * At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening； Exclusion Criteria: * A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)； * Previously received CD20-CD3 bispecific antibody treatment； * Previous allogeneic hematopoietic stem cell transplantation； * Previous solid organ transplantation； * History of autoimmune diseases； * Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)； * Patients with a history of progressive multifocal leukoencephalopathy (PML)； * A known or suspected history of CNS lymphoma (including primary or secondary)； * There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07081022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying B-cell Non-Hodgkin's Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07081022 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07081022 currently recruiting?
Yes, NCT07081022 is actively recruiting participants. Contact the research team at bang.an_peng@junshipharma.com for enrollment information.
Where is the NCT07081022 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07081022 clinical trial?
NCT07081022 is sponsored by Shanghai Junshi Bioscience Co., Ltd.. The trial plans to enroll 180 participants.